CoChat
Sign Up
Cited by 6Renal Diseases and GlomerulopathiesChronic Kidney Disease and DiabetesVasculitis and related conditions

The DOI matches its Crossref record; the references it cites are not checked yet.

The expanding role of biomarkers in the management of IgA nephropathy

Open access
Jain, Koyal, Rizk, Dana V.·2026·Kidney International Supplements
DOI 10.1016/j.kisu.2026.01.004PMC PMC13387147
Open this paper in CoChat — free account

Abstract

IgA nephropathy is the most prevalent glomerular disease worldwide. To date, a percutaneous kidney biopsy is needed for diagnosis and assessment of disease activity and prognosis. Histology and generic markers of kidney dysfunction, such as proteinuria, hematuria, and estimated glomerular filtration rate, are commonly used to assess kidney damage. Noninvasive biomarkers that can be used to provide diagnostic and prognostic information, enable risk stratification, guide treatment selection, and help monitor treatment response are greatly needed. On the basis of limited data, several promising novel biomarkers specifically related to IgA nephropathy pathophysiology have been proposed and need to be validated and standardized for use in routine clinical care. Once these biomarkers become available, the hope is that they will lead to early diagnosis of IgA nephropathy and provide more accurate prognosis of disease for individual patients. Given the complexity of the pathogenesis of IgA nephropathy, it seems likely that multiple biomarkers will need to be used to optimize patient care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.kisu.2026.01.004

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 110 · Cited by 6

Research works printed but not linked: 118

  1. D'Amico, 2003, Pathophysiology of proteinuria, Kidney Int, 63, 809, 10.1046/j.1523-1755.2003.00840.x · DOI
  2. D'Amico, 2004, Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome, Semin Nephrol, 24, 179, 10.1016/j.semnephrol.2004.01.001 · DOI
  3. Eitner, 2012, In search of a better understanding of IgA nephropathy-associated hematuria, Kidney Int, 82, 513, 10.1038/ki.2012.160 · DOI
  4. Lim, 2024, An update on current therapeutic options in IgA nephropathy, J Clin Med, 13, 947, 10.3390/jcm13040947 · DOI
  5. Holscher, 2023, Next-generation morphometry for pathomics—data mining in histopathology, Nat Commun, 14, 470, 10.1038/s41467-023-36173-0 · DOI
  6. Schena, 2018, Omics studies for comprehensive understanding of immunoglobulin A nephropathy: state-of-the-art and future directions, Nephrol Dial Transplant, 33, 2101, 10.1093/ndt/gfy130 · DOI
  7. Zheng, 2020, Single-cell transcriptomics reveal immune mechanisms of the onset and progression of IgA nephropathy, Cell Rep, 33, 10.1016/j.celrep.2020.108525 · DOI
  8. Tang, 2021, A partial picture of the single-cell transcriptomics of human IgA nephropathy, Front Immunol, 12, 10.3389/fimmu.2021.645988 · DOI
  9. Kiryluk, 2023, Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy, Nat Genet, 55, 1091, 10.1038/s41588-023-01422-x · DOI
  10. Li, 2023, Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis, BMC Med Genomics, 16, 63, 10.1186/s12920-023-01494-y · DOI
  11. Wimbury, 2024, Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial, Kidney Int, 105, 381, 10.1016/j.kint.2023.11.003 · DOI
  12. Selvaskandan, 2020, Monitoring immune responses in IgA nephropathy: biomarkers to guide management, Front Immunol, 11, 10.3389/fimmu.2020.572754 · DOI
  13. 2012, KDIGO clinical practice guideline for glomerulonephritis, Kidney Int Suppl, 2, 139
  14. Barbour, 2016, The MEST score provides earlier risk prediction in lgA nephropathy, Kidney Int, 89, 167, 10.1038/ki.2015.322 · DOI
  15. Trimarchi, 2017, Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group, Kidney Int, 91, 1014, 10.1016/j.kint.2017.02.003 · DOI
  16. Rovin, 2025, KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV), Kidney Int, 108, S1, 10.1016/j.kint.2025.04.004 · DOI · Paper page
  17. Hotta, 2002, Regression of IgA nephropathy: a repeat biopsy study, Am J Kidney Dis, 39, 493, 10.1053/ajkd.2002.31399 · DOI
  18. Shen, 2015, Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation, J Nephrol, 28, 441, 10.1007/s40620-014-0165-x · DOI
  19. Inker, 2016, Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis, Am J Kidney Dis, 68, 392, 10.1053/j.ajkd.2016.02.042 · DOI
  20. Thompson, 2019, Proteinuria reduction as a surrogate end point in trials of IgA nephropathy, Clin J Am Soc Nephrol, 14, 469, 10.2215/CJN.08600718 · DOI
  21. Reich, 2007, Remission of proteinuria improves prognosis in IgA nephropathy, J Am Soc Nephrol, 18, 3177, 10.1681/ASN.2007050526 · DOI
  22. Le, 2012, Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population, Nephrol Dial Transplant, 27, 1479, 10.1093/ndt/gfr527 · DOI
  23. Coppo, 2014, Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments, Kidney Int, 86, 828, 10.1038/ki.2014.63 · DOI
  24. 2021, KDIGO 2021 clinical practice guideline for the management of glomerular diseases, Kidney Int, 100, S1
  25. Pitcher, 2023, Long-term outcomes in IgA nephropathy, Clin J Am Soc Nephrol, 18, 727, 10.2215/CJN.0000000000000135 · DOI
  26. Lafayette, 2022, One-year estimated GFR slope independently predicts clinical benefit in immunoglobulin A nephropathy, Kidney Int Rep, 7, 2730, 10.1016/j.ekir.2022.09.017 · DOI
  27. Naresh, 2012, Day-to-day variability in spot urine protein-creatinine ratio measurements, Am J Kidney Dis, 60, 561, 10.1053/j.ajkd.2012.04.010 · DOI
  28. Canetta, 2026, Management of IgA nephropathy and the expanding role of immunomodulation, Kidney Int Suppl, 15, 14, 10.1016/j.kisu.2026.01.002 · DOI
  29. Zand, 2023, Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients, Clin Kidney J, 16, ii19, 10.1093/ckj/sfad232 · DOI
  30. Coppo, 2017, Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker, J Am Soc Nephrol, 28, 2831, 10.1681/ASN.2017060639 · DOI
  31. Schena, 1997, Survey of the Italian Registry of Renal Biopsies: frequency of the renal diseases for 7 consecutive years: the Italian Group of Renal Immunopathology, Nephrol Dial Transplant, 12, 418, 10.1093/ndt/12.3.418 · DOI
  32. Mizuno, 2021, Evaluation of red blood cell parameters provided by the UF-5000 urine auto-analyzer in patients with glomerulonephritis, Clin Chem Lab Med, 59, 1547, 10.1515/cclm-2021-0287 · DOI
  33. Cheung, 2026, IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis, Kidney Int Suppl, 15, 3, 10.1016/j.kisu.2026.01.003 · DOI · Paper page
  34. Barratt, 2020, Why target the gut to treat IgA nephropathy?, Kidney Int Rep, 5, 1620, 10.1016/j.ekir.2020.08.009 · DOI
  35. Selvaskandan, 2022, Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link, Int J Immunogenet, 49, 8, 10.1111/iji.12561 · DOI
  36. Boyd, 2012, An update on the pathogenesis and treatment of IgA nephropathy, Kidney Int, 81, 833, 10.1038/ki.2011.501 · DOI
  37. Cheung, 2025, The pathogenesis of IgA nephropathy and implications for treatment, Nat Rev Nephrol, 21, 9, 10.1038/s41581-024-00885-3 · DOI · Paper page
  38. Fan, 2018, The influence of environmental factors on clinical pathological changes of patients with immunoglobulin A nephropathy from different areas of China, Ren Fail, 40, 597, 10.1080/0886022X.2018.1532907 · DOI
  39. Suzuki, 2011, The pathophysiology of IgA nephropathy, J Am Soc Nephrol, 22, 1795, 10.1681/ASN.2011050464 · DOI
  40. Xu, 2023, An update on the genetics of IgA nephropathy, J Clin Med, 13, 123, 10.3390/jcm13010123 · DOI
  41. Kiryluk, 2014, The genetics and immunobiology of IgA nephropathy, J Clin Invest, 124, 2325, 10.1172/JCI74475 · DOI
  42. Canetta, 2014, Glomerular diseases: emerging tests and therapies for IgA nephropathy, Clin J Am Soc Nephrol, 9, 617, 10.2215/CJN.07260713 · DOI
  43. Moldoveanu, 2007, Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels, Kidney Int, 71, 1148, 10.1038/sj.ki.5002185 · DOI
  44. Smith, 2006, O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy, J Am Soc Nephrol, 17, 3520, 10.1681/ASN.2006060658 · DOI
  45. Tomana, 1999, Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies, J Clin Invest, 104, 73, 10.1172/JCI5535 · DOI
  46. Barratt, 2023, Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy, Expert Rev Clin Immunol, 19, 699, 10.1080/1744666X.2023.2206119 · DOI
  47. Zhao, 2012, The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression, Kidney Int, 82, 790, 10.1038/ki.2012.197 · DOI
  48. Wada, 2018, Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy, PLoS One, 13, 10.1371/journal.pone.0206865 · DOI
  49. Camilla, 2011, Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy, Clin J Am Soc Nephrol, 6, 1903, 10.2215/CJN.11571210 · DOI
  50. Yanagawa, 2014, A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases, PLoS One, 9, 10.1371/journal.pone.0098081 · DOI
  51. Gharavi, 2008, Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy, J Am Soc Nephrol, 19, 1008, 10.1681/ASN.2007091052 · DOI
  52. Eliasdottir, 2023, Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression, BMC Nephrol, 24, 160, 10.1186/s12882-023-03198-y · DOI
  53. Zeng, 2023, Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis, Front Immunol, 14, 10.3389/fimmu.2023.1209394 · DOI
  54. Barratt, 2025, Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy, J Am Soc Nephrol, 36, 679, 10.1681/ASN.0000000541 · DOI
  55. Lafayette, 2023, Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial, Lancet, 402, 859, 10.1016/S0140-6736(23)01554-4 · DOI
  56. Mathur, 2024, A phase 2 trial of sibeprenlimab in patients with IgA nephropathy, N Engl J Med, 390, 20, 10.1056/NEJMoa2305635 · DOI · Paper page
  57. Lafayette, 2024, A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy, Kidney Int, 105, 1306, 10.1016/j.kint.2024.03.012 · DOI
  58. Chan, 2023, Interim biomarker analysis from a randomized, double-blind, placebo-controlled, phase 2 trial of sibeprenlimab (VIS649) in participants with immunoglobulin A nephropathy, Kidney Int Rep, 8, S76, 10.1016/j.ekir.2023.02.169 · DOI
  59. Pohjonen, 2024, Indirect markers of intestinal damage in IgA nephropathy, Nephron, 148, 693, 10.1159/000538242 · DOI
  60. Li, 2023, Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis, Clin Kidney J, 16, 184, 10.1093/ckj/sfac214 · DOI
  61. Coppo, 2018, The gut–renal connection in IgA nephropathy, Semin Nephrol, 38, 504, 10.1016/j.semnephrol.2018.05.020 · DOI
  62. Gesualdo, 2021, The mucosal immune system and IgA nephropathy, Semin Immunopathol, 43, 657, 10.1007/s00281-021-00871-y · DOI
  63. Baert, 2018, The role of APRIL – a proliferation inducing ligand – in autoimmune diseases and expectations from its targeting, J Autoimmun, 95, 179, 10.1016/j.jaut.2018.10.016 · DOI
  64. Smulski, 2018, BAFF and BAFF-receptor in B cell selection and survival, Front Immunol, 9, 2285, 10.3389/fimmu.2018.02285 · DOI
  65. Cheung, 2023, The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies, Front Nephrol, 3
  66. Xin, 2013, Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features, J Nephrol, 26, 683, 10.5301/jn.5000218 · DOI
  67. Li, 2014, TLR9 and BAFF: their expression in patients with IgA nephropathy, Mol Med Rep, 10, 1469, 10.3892/mmr.2014.2359 · DOI
  68. Zhai, 2016, Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy, Medicine (Baltimore), 95, 10.1097/MD.0000000000003099 · DOI
  69. Han, 2016, The role of TNF superfamily member 13 in the progression of IgA nephropathy, J Am Soc Nephrol, 27, 3430, 10.1681/ASN.2015060677 · DOI
  70. Lv, 2023, Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria, Kidney Int Rep, 8, 499, 10.1016/j.ekir.2022.12.014 · DOI
  71. Kouri, 2021, Serum levels of miR-148b and Let-7b at diagnosis may have important impact in the response to treatment and long-term outcome in IgA nephropathy, J Clin Med, 10, 1987, 10.3390/jcm10091987 · DOI
  72. Serino, 2012, Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy, J Am Soc Nephrol, 23, 814, 10.1681/ASN.2011060567 · DOI
  73. Hennino, 2016, miR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy, Sci Rep, 6, 10.1038/srep27209 · DOI
  74. Hu, 2015, Increased miR-374b promotes cell proliferation and the production of aberrant glycosylated IgA1 in B cells of IgA nephropathy, FEBS Lett, 589, 4019, 10.1016/j.febslet.2015.10.033 · DOI
  75. Berthoux, 2012, Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy, J Am Soc Nephrol, 23, 1579, 10.1681/ASN.2012010053 · DOI
  76. Placzek, 2018, Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy, PLoS One, 13, 10.1371/journal.pone.0190967 · DOI
  77. Oguchi, 2024, Analysis of IgG subclass staining for IgG immunofluorescence-positive IgA nephropathy, Clin Nephrol, 102, 125, 10.5414/CN111352 · DOI
  78. Tian, 2021, Low serum IgG4 level: a potential diagnostic biomarker for IgA nephropathy, Ann Transl Med, 9, 781, 10.21037/atm-20-7007 · DOI
  79. Maixnerova, 2019, Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression, PLoS One, 14
  80. Berthoux, 2017, Prognostic value of serum biomarkers of autoimmunity for recurrence of IgA nephropathy after kidney transplantation, J Am Soc Nephrol, 28, 1943, 10.1681/ASN.2016060670 · DOI
  81. Suzuki, 2014, Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy, Clin Exp Nephrol, 18, 770, 10.1007/s10157-013-0921-6 · DOI
  82. Moura, 2001, Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy, J Exp Med, 194, 417, 10.1084/jem.194.4.417 · DOI · Paper page
  83. Moura, 2005, Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy, J Am Soc Nephrol, 16, 2667, 10.1681/ASN.2004111006 · DOI
  84. Jhee, 2021, CD71 mesangial IgA1 receptor and the progression of IgA nephropathy, Transl Res, 230, 34, 10.1016/j.trsl.2020.10.007 · DOI
  85. Faria, 2015, Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression, Clin Exp Immunol, 179, 354, 10.1111/cei.12461 · DOI
  86. Zhang, 2019, Clinical significance of galactose-deficient IgA1 by KM55 in patients with IgA nephropathy, Kidney Blood Press Res, 44, 1196, 10.1159/000502579 · DOI
  87. Chiu, 2021, Alternative complement pathway is activated and associated with galactose-deficient IgA(1) antibody in IgA nephropathy patients, Front Immunol, 12, 10.3389/fimmu.2021.638309 · DOI
  88. Oortwijn, 2006, Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy, J Am Soc Nephrol, 17, 3529, 10.1681/ASN.2006040388 · DOI
  89. Roos, 2006, Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease, J Am Soc Nephrol, 17, 1724, 10.1681/ASN.2005090923 · DOI
  90. Kim, 2012, Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy, PLoS One, 7
  91. Espinosa, 2014, Association of C4d deposition with clinical outcomes in IgA nephropathy, Clin J Am Soc Nephrol, 9, 897, 10.2215/CJN.09710913 · DOI
  92. Fabiano, 2017, Mesangial C4d deposition may predict progression of kidney disease in pediatric patients with IgA nephropathy, Pediatr Nephrol, 32, 1211, 10.1007/s00467-017-3610-y · DOI
  93. Medjeral-Thomas, 2018, Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor H-related protein-5 (FHR5) deposition, Kidney Int Rep, 3, 426, 10.1016/j.ekir.2017.11.015 · DOI
  94. Rizk, 2019, The emerging role of complement proteins as a target for therapy of IgA nephropathy, Front Immunol, 10, 504, 10.3389/fimmu.2019.00504 · DOI
  95. Liu, 2023, The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis, Front Immunol, 14
  96. Yang, 2021, The role of renal macrophage, AIM, and TGF-beta1 expression in renal fibrosis progression in IgAN patients, Front Immunol, 12
  97. Li, 2015, Clinical-pathologic significance of CD163 positive macrophage in IgA nephropathy patients with crescents, Int J Clin Exp Med, 8, 9299
  98. Gong, 2021, Urinary soluble CD163 levels predict IgA nephropathy remission status, Front Immunol, 12, 10.3389/fimmu.2021.769802 · DOI
  99. Li, 2024, Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy, Kidney Int Rep, 9, 3016, 10.1016/j.ekir.2024.07.031 · DOI
  100. Yoon, 2024, Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy, BMC Nephrol, 25, 142, 10.1186/s12882-024-03574-2 · DOI
  101. Kwon, 2013, KIM-1 expression predicts renal outcomes in IgA nephropathy, Clin Exp Nephrol, 17, 359, 10.1007/s10157-012-0707-2 · DOI
  102. Lin, 2014, Kidney injury molecule-1 expression in IgA nephropathy and its correlation with hypoxia and tubulointerstitial inflammation, Am J Physiol Renal Physiol, 306, F885, 10.1152/ajprenal.00331.2013 · DOI
  103. Zhou, 2023, Urinary epidermal growth factor predicts complete remission of proteinuria in Chinese children with IgA nephropathy, Pediatr Res, 94, 747, 10.1038/s41390-023-02542-0 · DOI
  104. Sparding, 2022, Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis, Nephrol Dial Transplant, 37, 1099, 10.1093/ndt/gfab163 · DOI
  105. Sparding, 2023, Unique biomarkers of collagen type III remodeling reflect different information regarding pathological kidney tissue alterations in patients with IgA nephropathy, Biomolecules, 13, 1093, 10.3390/biom13071093 · DOI
  106. Genovese, 2016, Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy, Nephrol Dial Transplant, 31, 472, 10.1093/ndt/gfv301 · DOI
  107. Liang, 2017, Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy, BMC Nephrol, 18, 63, 10.1186/s12882-017-0482-0 · DOI
  108. Duan, 2024, Blood and urine biomarkers of disease progression in IgA nephropathy, Biomark Res, 12, 72, 10.1186/s40364-024-00619-4 · DOI
  109. Wang, 2012, Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis, Am J Nephrol, 36, 412, 10.1159/000343452 · DOI
  110. Lee, 2023, Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis, Clin Kidney J, 16, ii1, 10.1093/ckj/sfad199 · DOI
  111. Yeo, 2019, Is immunoglobulin A nephropathy different in different ethnic populations?, Nephrology (Carlton), 24, 885, 10.1111/nep.13592 · DOI
  112. Yamagata, 2008, Chronic kidney disease perspectives in Japan and the importance of urinalysis screening, Clin Exp Nephrol, 12, 1, 10.1007/s10157-007-0010-9 · DOI
  113. Sukcharoen, 2020, IgA nephropathy genetic risk score to estimate the prevalence of IgA nephropathy in UK Biobank, Kidney Int Rep, 5, 1643, 10.1016/j.ekir.2020.07.012 · DOI
  114. Barbour, 2022, Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy, Kidney Int, 102, 160, 10.1016/j.kint.2022.02.042 · DOI
  115. Barbour, 2019, Evaluating a new international risk-prediction tool in IgA nephropathy, JAMA Intern Med, 179, 942, 10.1001/jamainternmed.2019.0600 · DOI
  116. Pawluczyk, 2021, Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression, Kidney Int, 99, 1127, 10.1016/j.kint.2020.12.028 · DOI
  117. Aldhouse, 2024, Development of a conceptual model for the patient experience of immunoglobulin A nephropathy (IgAN): a qualitative literature review, Adv Ther, 41, 1325, 10.1007/s12325-024-02793-1 · DOI
  118. Caster, 2023, Clinicopathological characteristics of adult IgA nephropathy in the United States, Kidney Int Rep, 8, 1792, 10.1016/j.ekir.2023.06.016 · DOI

Metadata

Authors
Jain, K., & Rizk, D. V.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • University of Alabama at Birmingham (US)
Corresponding author
Jain, Koyal
ORCID
Venue
Kidney International Supplements
Publisher
Elsevier BV
Published
2026-08
Volume
15
Issue
1
Pages
37-46
ISSN
2157-1716 (ISSN-L)
DOI
10.1016/j.kisu.2026.01.004
PMC
PMC13387147
OpenAlex
W7169773706
Cited by
6
References
110
Citations by year
2026: 6
FWCI
5.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Kidney International Supplements (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • UNC Libraries
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
IgA nephropathy, biomarkers, non-invasive biomarkers, disease activity assessment, prognosis, risk stratification, treatment response monitoring, early diagnosis, glomerular disease, proteinuria, hematuria, estimated glomerular filtration rate, renal biopsy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review